Association between the Severity of Nonalcoholic Fatty Liver Disease and High Sensitivity C-reactive Protein in Adults

Jina Yeo; Kyoung Kon Kim; In Cheol Hwang

Article

Korean J Obes 2012; 21(3): 166-174

Published online September 30, 2012

Association between the Severity of Nonalcoholic Fatty Liver Disease and High Sensitivity C-reactive Protein in Adults

Jina Yeo, Kyoung Kon Kim⁽¹⁾, In Cheol Hwang^(1)*

Author Affiliations

Gachon University, School of Medicine, Department of Family Medicine, Gachon University Gil Hospital⁽¹⁾

Abstract

Go to

Abstract
Figure
Table
References

Background: The relationship between nonalcoholic fatty liver disease (NAFLD) and serum high sensitivity C reactive protein (hs-CRP) is not well established, and very few studies have addressed the role of serum hs-CRP as a predictor of NAFLD severity.
Methods: We examined 3,905 subjects who visited a health promotion center and were over 19 years of age. A total of 948 subjects who satisfied the NAFLD criteria were included in the final analysis. Factors associated with serum hs-CRP level or affecting body fat distribution were excluded by testing total white blood cell count, serum creatinine level, and thyroid function. The subjects were categorized into 3 groups according to the amounts of hepatic fat contents. Hepatic steatosis was assessed by ultrasonography, and the diagnosis of metabolic syndrome was made on the basis of the National Cholesterol Education Program criteria. Metabolic risk factors and hs-CRP levels were analyzed.
Results: According to the NAFLD severity, 832 subjects were categorized as normal, 92 subjects were included in the mild to moderate NAFLD group, and 24 subjects were categorized into the severe group. As the NAFLD progressed to severe, the frequencies of metabolic risk factors and elevated hs-CRP level were increased (P-trend < 0.01). In univariate analysis, most metabolic risk factors were associated with NAFLD severity in both gender but the significance for elevated blood pressure and abnormal hs-CRP level were noted inonly females. After adjusting for potential confounding variables, such as other metabolic risks and liver function test, the association with NAFLD severity and serum hs-CRP level remained significant in females and in obese group (P-trend < 0.01).
Conclusions: According to the increment of hepatic steatosis, serum hs-CRP level as well as metabolic derangement was increased with significant trend in female and obese people.

Keywords: Non-alcoholic fatty liver disease, Severity, Hs-CRP, Metabolic risk factor

Figures

Go to

Abstract
Figure
Table
References

Fig. 1.

Adjusted^* mean hs-CRP levels according to the degree of non-alcoholic fatty liver disease in non-obese and obese group.

^*Adjusted for age, sex, body mass index, smoking, alcohol, exercise, high blood pressure, elevated glucose, hypertriglyceridemia, low HDL-C, AST, ALT, and GGT.

Hs-CRP, high sensitive C reactive protein; HDL-C, high density lipoprotein cholesterol; AST, aspartate transaminase; ALT, alanine transaminase; GGT, gamma glutamyltransferase.

Fig. 2.

Gender difference in association between serum hs-crp level and NAFLD severity.

P-trend was calculated using multiple logistic regression analysis after adjusting abnormal alanine transaminase and metabolic components, such as high blood pressure, elevated fasting glucose, hypertriglyceridemia, low HDL-C, and body mass index.

Hs-CRP, high sensitive C reactive protein; HDL-C, high density lipoprotein cholesterol; NAFLD, non-alcoholic fatty liver disease.

Tables

Go to

Abstract
Figure
Table
References

Demographic and biochemical characteristics of the subjects according to the severity of non-alcoholic fatty liver disease

Metabolic features according to the severity of non-alcoholic fatty liver disease

Univariate analysis between the severity of non-alcoholic fatty liver disease* and several variables in male and female

References

Go to

Abstract
Figure
Table
References

Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, the metabolic syndrome. Hepatology 2003;37:917-23.
Ford ES, Li C, Zhao G, Tsai J. Trends in obesity and abdominal obesity among adults in the United States from 1999-2008. Int J Obes (Lond) 2011;35:736-43.
Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006;21:138-43.
Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52.
Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005;22:1129-33.
Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006;44:1167-74.
Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005;25:779-86.
Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007;49:2129-38.
Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000;23:1835 -9.
Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-54.
Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Perez-Ayuso RM, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int 2009;29:82-8.
Kogiso T, Moriyoshi Y, Shimizu S, Nagahara H, Shiratori K. High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population. J Gastroenterol 2009;44:313-21.
Tchernof A, Poehlman ET, Despres JP. Body fat distribution, the menopause transition, hormone replacement therapy. Diabetes Metab 2000;26:12-20.
Yoo VY. Quality of midbeyond women's life. J Korean Soc Menopause 1996;2:45-57.
Hwang IC, Suh SY, Suh AR, Ahn HY. The relationship between normal serum uric acid and nonalcoholic fatty liver disease. J Korean Med Sci 2011;26:386-91.
Longo D, Fauci A, Kasper D, Hause S, Jameson J, Loscalzo J. Harrison's principles of internal medicine. 18th ed. London: McGraw-Hill; 2012.
Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986;292:13-5.
Choi SH, Kim DJ, Lee KE, Kim YM, Song YD, Kim HD, et al. Cut-off value of waist circumference for metabolic syndrome patients in Korean adult population. Korean J Obes 2004;13:53-60.
Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342:1266-71.
Tonstad S, Cowan JL. C-reactive protein as a predictor of disease in smokers and former smokers: a review. Int J Clin Pract 2009;63:1634-41.
Wener MH, Daum PR, McQuillan GM. The influence of age, sex, race on the upper reference limit of serum C-reactive protein concentration. J Rheumatol 2000;27:2351-9.
Cartier A, Cote M, Lemieux I, Perusse L, Tremblay A, Bouchard C, et al. Sex differences in inflammatory markers: what is the contribution of visceral adiposity? Am J Clin Nutr 2009;89:1307-14.
Lowe GD, Yarnell JW, Rumley A, Bainton D, Sweetnam PM. C-reactive protein, fibrin D-dimer, incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 2001;21:603-10.
Liu J, Fox CS, Hickson DA, May WD, Hairston KG, Carr JJ, et al. Impact of abdominal visceral and subcutaneous adipose tissue on cardiometabolic risk factors: the Jackson Heart Study. J Clin Endocrinol Metab 2010;95:5419-26.
Cheung B. Hypertension as part of the metabolic syndrome. J Hum Hypertens 2008;22:871-4.
Yanai H, Tomono Y, Ito K, Furutani N, Yoshida H, Tada N. The underlying mechanisms for development of hypertension in
Montecucco F, Mach F. New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor. Clin Interv Aging 2008;3:341-9.
Svoboda DS, Kawaja MD. Changes in hepatic protein expression in spontaneously hypertensive rats suggest early stages of non-alcoholic fatty liver disease. J Proteomics 2012;75:1752-63.
Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986;220:83-8.
Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004;164:2169-75.
Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-57.